Ono Pharmaceutical Co., Ltd. (TYO:4528)
1,591.00
+10.00 (0.63%)
Jul 10, 2025, 3:30 PM JST
Ono Pharmaceutical Revenue
In the fiscal year ending March 31, 2025, Ono Pharmaceutical had annual revenue of 486.87B JPY, down -3.14%. Ono Pharmaceutical had revenue of 112.31B in the quarter ending March 31, 2025, a decrease of -0.41%.
Revenue
486.87B
Revenue Growth
-3.14%
P/S Ratio
1.53
Revenue / Employee
113.57M
Employees
4,287
Market Cap
742.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 486.87B | -15.80B | -3.14% |
Mar 31, 2024 | 502.67B | 55.49B | 12.41% |
Mar 31, 2023 | 447.19B | 85.83B | 23.75% |
Mar 31, 2022 | 361.36B | 52.08B | 16.84% |
Mar 31, 2021 | 309.28B | 16.86B | 5.77% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Takeda Pharmaceutical Company | 4,581.55B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 866.03B |
Terumo | 1,036.17B |
Otsuka Holdings | 2,393.18B |
Astellas Pharma | 1,912.32B |
Shionogi & | 438.27B |
Ono Pharmaceutical News
- 17 days ago - Vertex and Ono Pharmaceutical form exclusive alliance for Povetacicept in Japan and South Korea - Seeking Alpha
- 17 days ago - Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Benzinga
- 17 days ago - Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Business Wire
- 2 months ago - Ono Pharmaceutical Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Ono Pharmaceutical reports FY results - Seeking Alpha
- 3 months ago - What's Going On With Cue Biopharma Shares Tuesday? - Benzinga
- 4 months ago - Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - Benzinga
- 4 months ago - Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - Seeking Alpha